Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flezian Plus
- Development stage
- Preclinical
- Lead developer
- Provident Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flezian Plus is a fixed-dose combination small molecule therapy distributed by Provident Pharmaceuticals for the management of type 2 diabetes mellitus. It consists of two antihyperglycemic agents: empagliflozin and metformin. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, thereby increasing urinary glucose excretion. Metformin is a biguanide that lowers blood glucose levels by inhibiting hepatic gluconeogenesis (via mitochondrial complex I inhibition and subsequent AMPK activation), decreasing intestinal glucose absorption, and improving insulin sensitivity. This combination provides a synergistic approach to glycemic control by targeting both renal and metabolic pathways.
- Brand names
- FLEZIAN PLUS
- Other names
- empagliflozin + metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on Flezian Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flezian Plus.